佐力药业
(300181)
| 流通市值：87.17亿 | | | 总市值：101.70亿 |
| 流通股本：6.01亿 | | | 总股本：7.01亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 672,899,096.57 | 1,942,440,446.03 | 1,464,947,132.5 | 1,011,458,568.59 |
| 营业收入 | 672,899,096.57 | 1,942,440,446.03 | 1,464,947,132.5 | 1,011,458,568.59 |
| 二、营业总成本 | 519,085,030.36 | 1,577,626,225.74 | 1,188,305,385.08 | 820,542,149.95 |
| 营业成本 | 224,227,569.29 | 613,341,640.53 | 459,312,143.43 | 310,374,096.09 |
| 税金及附加 | 4,948,454.13 | 24,975,104.16 | 16,501,923.96 | 12,020,076.78 |
| 销售费用 | 250,541,152.26 | 777,486,314.95 | 597,941,105.01 | 420,669,513.07 |
| 管理费用 | 25,823,312.46 | 96,693,571.96 | 67,577,986.07 | 44,412,275.44 |
| 研发费用 | 14,564,920.81 | 79,381,880.22 | 58,183,284.31 | 40,436,334 |
| 财务费用 | -1,020,378.59 | -14,252,286.08 | -11,211,057.7 | -7,370,145.43 |
| 其中:利息费用 | 2,053,100.17 | 7,622,885.65 | 6,012,944.64 | 3,915,085.06 |
| 其中:利息收入 | 3,185,151.71 | 21,997,421.5 | 17,342,268.01 | 11,347,864.3 |
| 加:投资收益 | 289,929.8 | -100,726.08 | -290,251.66 | -271,853.03 |
| 资产处置收益 | 6,878 | 279,126.15 | 240,442.04 | 240,442.04 |
| 资产减值损失(新) | - | -3,020,148.87 | - | - |
| 信用减值损失(新) | -7,033,566.99 | -545,368.28 | -327,880.65 | -951,066.62 |
| 其他收益 | 29,351,106.22 | 87,279,879.92 | 61,146,252.39 | 39,210,410.36 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 176,428,413.24 | 448,706,983.13 | 337,410,309.54 | 229,144,351.39 |
| 加:营业外收入 | 93,960.48 | 164,949.32 | 56,868.1 | 10.08 |
| 减:营业外支出 | 10,237,226.53 | 2,230,174.09 | 1,243,518.11 | 433,878.06 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 166,285,147.19 | 446,641,758.36 | 336,223,659.53 | 228,710,483.41 |
| 减:所得税费用 | 22,178,653.43 | 55,878,836.7 | 43,639,960.99 | 26,935,288.88 |
| 六、净利润 | 144,106,493.76 | 390,762,921.66 | 292,583,698.54 | 201,775,194.53 |
| 持续经营净利润 | 144,106,493.76 | 390,762,921.66 | 292,583,698.54 | 201,775,194.53 |
| 归属于母公司股东的净利润 | 142,415,333.77 | 382,936,093.79 | 286,865,191.49 | 197,661,591.44 |
| 少数股东损益 | 1,691,159.99 | 7,826,827.87 | 5,718,507.05 | 4,113,603.09 |
| (一)基本每股收益 | 0.2 | 0.55 | 0.41 | 0.28 |
| (二)稀释每股收益 | 0.2 | 0.55 | 0.41 | 0.28 |
| 八、其他综合收益 | -8,822,828.12 | -159,481,204.12 | -121,960,107 | -94,680,776.37 |
| 归属于母公司股东的其他综合收益 | -8,161,468.92 | -147,526,493.06 | -112,817,977.38 | -87,583,505.37 |
| 九、综合收益总额 | 135,283,665.64 | 231,281,717.54 | 170,623,591.54 | 107,094,418.16 |
| 归属于母公司股东的综合收益总额 | 134,253,864.85 | 235,409,600.73 | 174,047,214.11 | 110,078,086.07 |
| 归属于少数股东的综合收益总额 | 1,029,800.79 | -4,127,883.19 | -3,423,622.57 | -2,983,667.91 |
| 公告日期 | 2024-04-19 | 2024-04-19 | 2023-10-23 | 2023-08-09 |
| 审计意见(境内) | | 标准无保留意见 | | |